Skip to content
Menu

NeuroSense Therapeutics Announces Its Phase 2B PARADIGM Study Of PrimeC In Amyotrophic Lateral Sclerosis Has Met Its Primary Efficacy Endpoint

Benzinga Newsdesk 4 months ago

News

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

First randomized, double-blind, placebo-controlled trial to demonstrate treatment-associated reduction of TDP-43 in people living with ALSTDP-43 pathology is present in more than 97% of ALS cases and is widely

  • First randomized, double-blind, placebo-controlled trial to demonstrate treatment-associated reduction of TDP-43 in people living with ALS
  • TDP-43 pathology is present in more than 97% of ALS cases and is widely recognized as a central driver of disease progression
  • PrimeC demonstrates target engagement with consistent effects across clinical outcomes, survival, and biomarkers, supporting its potential as a disease-modifying therapy

Read at benzinga.com